KOPS - The Institutional Repository of the University of Konstanz

Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression : Results From the AGOPSYCH Study

Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression : Results From the AGOPSYCH Study

Cite This

Files in this item

Files Size Format View

There are no files associated with this item.

ENGLISCH, Susanne, Hanna Sophie JUNG, Sarah EISENACHER, Antje LEWIEN, Anna BECKER, Ulrike NOWAK, Hanna BRAUN, Jascha THIEM, Andreas MEYER-LINDENBERG, Mathias ZINK, 2018. Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression : Results From the AGOPSYCH Study. In: Journal of Clinical Psychopharmacology. 38(4), pp. 357-361. ISSN 0271-0749. eISSN 1533-712X. Available under: doi: 10.1097/JCP.0000000000000909

@article{Englisch2018-08Neuro-45464, title={Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression : Results From the AGOPSYCH Study}, year={2018}, doi={10.1097/JCP.0000000000000909}, number={4}, volume={38}, issn={0271-0749}, journal={Journal of Clinical Psychopharmacology}, pages={357--361}, author={Englisch, Susanne and Jung, Hanna Sophie and Eisenacher, Sarah and Lewien, Antje and Becker, Anna and Nowak, Ulrike and Braun, Hanna and Thiem, Jascha and Meyer-Lindenberg, Andreas and Zink, Mathias} }

Becker, Anna Jung, Hanna Sophie Meyer-Lindenberg, Andreas Eisenacher, Sarah Background Cognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT<sub>1</sub>/MT<sub>2</sub> receptors and antagonist at 5-HT<sub>2C</sub> receptors, increases dopamine and norepinephrine in the prefrontal cortex and may therefore have the potential of improving neurocognition in patients with schizophrenia.<br /><br />Methods Twenty-seven patients with schizophrenia and comorbid depression were treated with AGO in addition to stable doses of antipsychotic drugs. Cognitive abilities were assessed with the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) at study entry and after 12 weeks of AGO treatment after the intention-to-treat principle.<br /><br />Results We observed statistically significant yet clinically negligible increases of the MCCB composite score and the reasoning/problem solving subscore. Patients with unimpaired sleep at baseline showed greater improvements over time than those with sleep disturbances. Changes on the MCCB were not correlated with other psychometric variables.<br /><br />Conclusions Despite statistically significant, cognitive improvements after 12 weeks of AGO treatment were clinically irrelevant. Our findings may be limited by baseline properties of the study sample and the study design. In particular, lacking a control group, it cannot be ruled out that improvements were unrelated to AGO treatment. That is why randomized controlled trials are needed to validate the relevance of AGO as a cognitive enhancer in schizophrenia. Nowak, Ulrike Eisenacher, Sarah eng Braun, Hanna Lewien, Antje Nowak, Ulrike Becker, Anna Jung, Hanna Sophie Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression : Results From the AGOPSYCH Study Braun, Hanna Thiem, Jascha 2019-03-13T15:54:02Z Meyer-Lindenberg, Andreas Englisch, Susanne Zink, Mathias 2018-08 2019-03-13T15:54:02Z Englisch, Susanne Thiem, Jascha Lewien, Antje Zink, Mathias

This item appears in the following Collection(s)

Search KOPS


Browse

My Account